ArticleAmerican journal of translational research2025
Albumin ratio and liver-to-abdominal area ratio are promising prognostic indicators for patients with post-hepatitis B cirrhosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical relevance of the Albumin Ratio (AR) and Liver-to-Abdominal Area Ratio (LAAR) as prognostic markers for patients with hepatitis B-related cirrhosis.
methodsA retrospective cohort study was conducted on 278 patients diagnosed with hepatitis B-associated cirrhosis at Baoji Central Hospital from January 2017 to December 2020. Clinical data, laboratory results (AR), and imaging data (LAAR) were collected. Prognostic value of AR and LAAR was assessed using Kaplan-Meier survival analysis, Cox proportional hazards regression, and receiver operating characteristic (ROC) curves. A nomogram integrating multiple variables was developed and validated to dynamically predict 6-, 12-, and 24-month survival outcomes.
resultsBoth AR and LAAR were significantly reduced in the deceased group compared to survivors (P<0.05). Cox regression analysis identified AR (HR=1.86, 95% CI: 1.40-2.45, P<0.001) and LAAR (HR=1.67, 95% CI: 1.25-2.22, P=0.002) as independent prognostic factors. Kaplan-Meier survival curves revealed significantly shorter survival in patients with lower AR and LAAR (P<0.001). Time-dependent ROC analysis indicated good predictive performance for AR (AUC up to 0.85), while LAAR showed relatively low discrimination, with AUCs ranging from 0.507 to 0.623. The nomogram, incorporating both AR and LAAR, exhibited excellent discrimination (C-index =0.950), and its predictive accuracy was validated through calibration curves.
conclusionAR and LAAR are critical prognostic indicators in hepatitis B-related cirrhosis. The nomogram model, integrating these values, supports tailored treatment plans and monitoring strategies in clinical settings. Patients with lower AR and LAAR have poorer survival outcomes, and the model's robust predictive capacity has been validated, enhancing precision in patient management and supporting individualized therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.